CVS Health Corporation — FY2017 Form 10-K
Reporting period: Fiscal year ended December 31, 2017. This is an annual filing, not a standalone fourth-quarter report. Amounts below are in millions of dollars except per-share data. The supplied filing text incorporates the full financial statements and MD&A by reference; it does not reproduce detailed cash flow or liquidity figures.
Business context
CVS Health operates Pharmacy Services, Retail/LTC, and Corporate segments, combining pharmacy benefit management, retail and specialty pharmacies, long-term care pharmacy, and walk-in clinics. At year-end it reported 9,803 retail locations, 1,134 MinuteClinic locations, and a PBM serving more than 94 million plan members.
Key financial metrics
| Metric | 2017 | 2016 | Change |
|---|---|---|---|
| Net revenue | $184,765 | $177,526 | +4.1% |
| Gross profit | $28,545 | $28,857 | -1.1% |
| Operating profit | $9,517 | $10,366 | -8.2% |
| Net income attributable to CVS Health | $6,622 | $5,317 | +24.5% |
| Diluted EPS | $6.44 | $4.90 | +31.4% |
| Interest expense, net | $1,041 | $1,058 | -1.6% |
| Long-term debt at year-end | $22,181 | $25,615 | -13.4% |
| Total assets at year-end | $95,131 | $94,462 | +0.7% |
| Total shareholders’ equity at year-end | $37,695 | $36,834 | +2.3% |
Calculated margins: Gross margin was approximately 15.5% in 2017 versus 16.3% in 2016; operating margin was approximately 5.2% versus 5.8%. Net margin was approximately 3.6% versus 3.0%. These percentages are calculated from the reported figures.
Cash flow, cash balances, current liabilities, and specific liquidity ratios are not clearly provided in the supplied filing text. The filing describes funding through operating cash flow, commercial paper and other short-term borrowings, sale-leasebacks, and long-term debt. It also notes that Medicare Part D settlements with CMS can affect working capital across periods.
Material changes versus 2016
- Revenue grew 4.1%, while gross profit and operating profit declined, consistent with lower reported margins.
- Net income and diluted EPS increased substantially. The income tax provision fell to $1,637 from $3,317; the supplied text does not provide a clear explanation for the decrease.
- Long-term debt declined by $3,434. The company repurchased 55.4 million shares for approximately $4.4 billion during 2017, then suspended repurchases in the fourth quarter in connection with the proposed Aetna acquisition.
- Cash dividends were $2.00 per share for 2017, up from $1.70 in 2016.
Outlook, risks, and unusual items
- Proposed Aetna acquisition: Announced December 3, 2017, with consideration of $145 cash and 0.8378 CVS shares per Aetna share. The filing valued Aetna at approximately $69 billion, or approximately $77 billion including assumed debt. Closing was projected for the second half of 2018, subject to shareholder, antitrust, insurance, and other regulatory approvals.
- CVS expected to incur approximately $45 billion of new acquisition debt and assume approximately $8.2 billion of Aetna debt if the transaction closed. Management projected the deal would be accretive to EPS in the second full year after closing, but noted that estimates could change and dilution remained possible.
- Key stated risks include PBM and pharmacy margin pressure; competition and client retention; reimbursement and drug-pricing changes; evolving health-care regulation; Medicare Part D exposure; supplier and drug availability; cybersecurity and privacy; litigation; and execution and integration risks related to Aetna. CVS cited $52.1 billion of goodwill and other intangible assets, which could be subject to impairment.
- The filing reports ongoing legal and regulatory exposure, including consent decrees and compliance agreements. It identifies New York environmental claims concerning alleged historical hazardous-waste noncompliance at long-term care pharmacies, which it said were not material to the business or financial position.
- The company said its disclosure controls were adequate and effective at a reasonable assurance level and reported no fourth-quarter changes in internal control over financial reporting that materially affected, or were reasonably likely to materially affect, those controls.
Investor verification priorities
- Review the incorporated 2017 annual report financial statements and MD&A for operating cash flow, free cash flow, cash and short-term debt, segment results, and the specific drivers of the lower tax provision and operating profit.
- Track Aetna transaction approvals, final financing and purchase terms, expected synergies, integration costs, and the effect of acquisition debt on leverage, ratings, dividends, and capital returns.
- Assess whether revenue growth can be sustained while gross and operating margins are under pressure, including the impact of client renewals, reimbursement rates, generic drug costs, and manufacturer rebates.
- Review disclosures on material litigation, government audits and compliance agreements, and cybersecurity or privacy incidents for developments beyond the items summarized here.